🔗 Share this article

A shadow market for unlicensed slimming drugs is being driven by TikTok fitness influencers and sellers on communication apps, based on new investigations.

Experimental Treatment Acquiring Popularity Online

Retatrutide, which remains in clinical trials, is being promoted by online personalities for its alleged fat-burning properties. Followers are encouraged to message these accounts directly for source information, while also receiving promotional offers.

Thriving Commerce on Messaging Platforms

Separately, a robust trade exists on messaging services, where groups with numerous of participants share comparison photos, injection guides and claims of next-day UK delivery. Vendors market the substance there before directing buyers to other platforms for purchases.

Learning About The Experimental Drug

Retatrutide is an experimental injectable created by US drugmaker Eli Lilly. The drug targets three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies indicate it could assist individuals reduce up to a quarter of their total weight. Nicknamed the “triple G”, the substance is being promoted online as the next Ozempic.

Medical Experts Express Worries

However, doctors and chemists have warned that the distribution of what is still an unlicensed drug in the United Kingdom is a cause for concern and could result in users administering substances of uncertain source.

Some professionals stated the popularity for retatrutide could be linked to the increasing cost of licensed weight loss products such as Mounjaro.

Legal Status and Implementation

Selling the unapproved drug on social media or messaging apps is prohibited in the UK, as it is an unapproved medication that must not be promoted or supplied for human use under the Human Medicines Regulations 2012.

Several content creators try to sidestep the rules by referring to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted substance, but advertising and distribution can still violate pharmaceutical, advertising, and consumer regulations, potentially leading to fines, prosecution or imprisonment.

Platform Response and Content Removal

According to the social media company, the platform has removed violative material and prohibited associated keywords and query recommendations. The company said it was dedicated to keeping the platform safe and allocating resources in strengthening enforcement strategies.

Online Marketplace Activities

Investigations also discovered groups with up to nine thousand participants selling the experimental drug using the platform's built-in discovery tool, which operates like a online catalog. Typing “retatrutide” immediately brings up channels with numerous of users, populated with photos of slimming results, positive reviews and step-by-step instructions for preparing or administering at home.

After moments of joining one group, a vendor posted WhatsApp details, where most purchases occur. The seller sent an instruction manual and guaranteed delivery within two days. When asked whether the substance was genuine, one vendor responded: “You can’t be sure.” Another shared a image of a alleged testing documentation. None asked about weight, medical conditions or previous experience.

Item Details and Costs

Within these groups, posts display black plastic packages with Royal Mail stickers, claiming to contain fresh supplies. One message stated: “It took eight of us to load them this morning.”

Customers can choose between powder vials, prepared at home with sterile water, or ready-to-use pens usually sold at 160 pounds for 20 milligrams. When asked how long a pen should be used, vendors give conflicting responses varying between a several days to “depends on your body”.

Platform Oversight and Security Actions

A spokesperson for Telegram stated it regularly monitored dangerous material on its platform including content that encouraged the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”.

Medical Professional Warnings

“People are injecting materials they cannot confirm. Although the science behind this drug is sound, these online versions may not include what they advertise,” stated Jason Murphy, the director of pharmaceutical services at Chemist4U.

Dr Crystal Wyllie of Asda Online Doctor connected the surge in demand to recent price rises for authorized weight-loss drugs such as Mounjaro. “With prices rising, individuals are using social media. But fake treatments are highly risky. You can’t be certain what’s contained or whether the conditions they were produced in was sterile,” she said.

Her staff has already encountered patients harmed by personal administration from unverified sources. “We recognize the frustration, but buying from Telegram or communication platforms is gambling with your health,” said Wyllie. “These materials could be impure or incorrectly dosed.”

Producer Statement

A representative from the pharmaceutical company said the substance was in phase 3 clinical trials and had not been reviewed or authorized by any regulatory agency globally. “Therefore at this point no one can sell [it] for personal consumption,” they explained, noting that any item “misleadingly claiming itself as a Lilly investigational substance not yet authorized … may subject patients to potentially significant medical dangers”.